AR036154A1 - Anticuerpos especificos de cd44v6. - Google Patents
Anticuerpos especificos de cd44v6.Info
- Publication number
- AR036154A1 AR036154A1 ARP020101830A ARP020101830A AR036154A1 AR 036154 A1 AR036154 A1 AR 036154A1 AR P020101830 A ARP020101830 A AR P020101830A AR P020101830 A ARP020101830 A AR P020101830A AR 036154 A1 AR036154 A1 AR 036154A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- variants
- seq
- fragments
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Anticuerpos con una secuencia especificada, que son específicos de un epítopo que está codificado por el exón v6 variante del gen CD44 y a derivados de dicho anticuerpo. También proporciona moléculas de ácido nucleico que codifican dichas proteínas anticuerpo. Además concierne a métodos para producir dichas proteínas anticuerpo. También proporciona composiciones farmacéuticas que comprenden dichas proteínas anticuerpo. Además está relacionado con la aplicación en la fabricación de un medicamento para el tratamiento del cáncer. Reivindicación 1: Una molécula de anticuerpo que comprende una región variable de la cadena pesada caracterizada por la secuencia de aminoácidos definida en la SEQ ID No. 1, o uno de sus fragmentos, variantes alélicas, variantes funcionales, variantes de glicosilación, moléculas de fusión o derivados químicos. Reivindicación 3: Una molécula de anticuerpo que comprende una región variable de la cadena ligera caracterizada por la secuencia de aminoácidos definida en la SEQ ID No. 2, o uno de sus fragmentos, variantes alélicas, variantes funcionales, variantes de glicosilación, moléculas de fusión o derivados químicos. Reivindicación 39: La proteína anticuerpo de la reivindicación 38, en la que dicho agente terapéutico es un agente terapéutico seleccionado entre el grupo constituido por radioisótopos, toxinas, toxoides, agentes inflamatorios y agentes quimioterapéuticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112237 | 2001-05-18 | ||
| US32514701P | 2001-09-26 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036154A1 true AR036154A1 (es) | 2004-08-18 |
Family
ID=33442672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101830A AR036154A1 (es) | 2001-05-18 | 2002-05-17 | Anticuerpos especificos de cd44v6. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397387A1 (es) |
| JP (1) | JP2005504517A (es) |
| CN (1) | CN1541226A (es) |
| AR (1) | AR036154A1 (es) |
| BR (1) | BR0210905A (es) |
| CA (1) | CA2443437A1 (es) |
| CZ (1) | CZ20033476A3 (es) |
| EA (1) | EA200301169A1 (es) |
| EC (1) | ECSP034838A (es) |
| EE (1) | EE200300569A (es) |
| HU (1) | HUP0400030A3 (es) |
| MX (1) | MXPA03010523A (es) |
| PE (1) | PE20021098A1 (es) |
| PL (1) | PL365735A1 (es) |
| SK (1) | SK15592003A3 (es) |
| WO (1) | WO2002094879A1 (es) |
| YU (1) | YU91403A (es) |
| ZA (1) | ZA200307365B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP1716179A2 (en) | 2004-02-12 | 2006-11-02 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| EP2322560B1 (en) | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| JP2009521206A (ja) | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| SI2167038T1 (en) * | 2007-06-13 | 2018-08-31 | Zymogenetics, Inc. | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus |
| EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
| PT2531527E (pt) | 2010-02-04 | 2014-05-16 | Hoffmann La Roche | Anticorpo monoclonal contra cd44 para ser utilizado no tratamento de carcinoma de células escamosas da cabeça e do pescoço |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
| WO2017215637A1 (zh) * | 2016-06-15 | 2017-12-21 | 李翀 | 一种人子宫内膜癌的标志物、抗体及其应用 |
| CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
| US20250326855A1 (en) * | 2021-03-05 | 2025-10-23 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| CA2149635A1 (en) * | 1992-11-20 | 1994-06-09 | David Tarin | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
| UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
-
2002
- 2002-05-17 PL PL02365735A patent/PL365735A1/xx not_active Application Discontinuation
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/pt not_active IP Right Cessation
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/ja active Pending
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/es unknown
- 2002-05-17 AR ARP020101830A patent/AR036154A1/es unknown
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/hu unknown
- 2002-05-17 EE EEP200300569A patent/EE200300569A/xx unknown
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/cs unknown
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/sk not_active Application Discontinuation
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Ceased
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 EA EA200301169A patent/EA200301169A1/ru unknown
- 2002-05-17 YU YU91403A patent/YU91403A/sh unknown
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/es not_active Application Discontinuation
- 2002-05-17 CN CNA028101561A patent/CN1541226A/zh active Pending
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/xx unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0210905A (pt) | 2004-06-08 |
| ZA200307365B (en) | 2004-05-10 |
| CA2443437A1 (en) | 2002-11-28 |
| YU91403A (sh) | 2006-05-25 |
| CZ20033476A3 (cs) | 2004-05-12 |
| HUP0400030A3 (en) | 2006-02-28 |
| EA200301169A1 (ru) | 2004-06-24 |
| HUP0400030A2 (hu) | 2004-04-28 |
| EE200300569A (et) | 2004-04-15 |
| JP2005504517A (ja) | 2005-02-17 |
| MXPA03010523A (es) | 2004-07-01 |
| SK15592003A3 (sk) | 2004-06-08 |
| ECSP034838A (es) | 2003-12-24 |
| EP1397387A1 (en) | 2004-03-17 |
| PE20021098A1 (es) | 2003-02-11 |
| CN1541226A (zh) | 2004-10-27 |
| WO2002094879A1 (en) | 2002-11-28 |
| PL365735A1 (en) | 2005-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050376A1 (es) | Anticuerpos dirigidos a m-csf | |
| ECSP044978A (es) | ANTICUERPOS HUMANOS ANTAGONISTAS CONTRA hTNFSF13b | |
| ATE510011T1 (de) | Neue pilzproteine und diese codierende nukleinsäuren | |
| ECSP14011269A (es) | Formulaciones de anticuerpos y proteínas de alta concentración | |
| AR047717A1 (es) | Anticuerpos dirigidos a c-met | |
| WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
| EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
| PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 | |
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| AR045056A1 (es) | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf | |
| AR086272A2 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| PY0132240A (es) | Anticuerpos contra el receptor del factor de crecimiento similar a insulina | |
| EA200870020A1 (ru) | Человеческие моноклональные антитела против о8е | |
| ATE444361T1 (de) | Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen | |
| AR030236A1 (es) | Moléculas similares a il-17 y usos de las mismas | |
| ATE209680T1 (de) | Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen | |
| JP2005504517A5 (es) | ||
| BG101024A (bg) | Моноклонално антитяло срещу сd44v6 | |
| EA200701947A1 (ru) | Легкая фармацевтическая вода, терапевтические композиции, ее содержащие, способы их производства и применения | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| BR0113099A (pt) | Gene e proteìna relacionados com esquizofrenia | |
| AR004360A1 (es) | Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas. | |
| CO4520255A1 (es) | Terapia de tumores mediante linfocitos t citotoxicos de transferencia adoptivos especificos de cd44v |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |